FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3137718127> ?p ?o ?g. }

• W3137718127 abstract "Abstract Background The introduction of programmed cell death protein 1 (PD-1) blockers (i.e. nivolumab and pembrolizumab) has significantly improved the prognosis of patients with advanced melanoma. However, the long treatment duration (i.e. two years or longer) has a high impact on patients and healthcare systems in terms of (severe) toxicity, health-related quality of life (HRQoL), resource use, and healthcare costs. While durable tumour responses have been observed and PD-1 blockade is discontinued on an individual basis, no consensus has been reached on the optimal treatment duration. The objective of the Safe Stop trial is to evaluate whether early discontinuation of first-line PD-1 blockade is safe in patients with advanced and metastatic melanoma who achieve a radiological response. Methods The Safe Stop trial is a nationwide, multicentre, prospective, single-arm, interventional study in the Netherlands. A total of 200 patients with advanced and metastatic cutaneous melanoma and a confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumours (RECIST) v1.1 will be included to early discontinue first-line monotherapy with nivolumab or pembrolizumab. The primary objective is the rate of ongoing responses at 24 months after discontinuation of PD-1 blockade. Secondary objectives include best overall and duration of response, need and outcome of rechallenge with PD-1 blockade, and changes in (serious) adverse events and HRQoL. The impact of treatment discontinuation on healthcare resource use, productivity losses, and hours of informal care will also be assessed. Results will be compared to those from patients with CR or PR who completed 24 months of treatment with PD-1 blockade and had an ongoing response at treatment discontinuation. It is hypothesised that it is safe to early stop first-line nivolumab or pembrolizumab at confirmed tumour response while improving HRQoL and reducing costs. Discussion From a patient, healthcare, and economic perspective, shorter treatment duration is preferred and overtreatment should be prevented. If early discontinuation of first-line PD-1 blockade appears to be safe, early discontinuation of PD-1 blockade may be implemented as the standard of care in a selected group of patients. Trial registration The Safe Stop trial has been registered in the Netherlands Trial Register (NTR), Trial NL7293 (old NTR ID: 7502), https://www.trialregister.nl/trial/7293 . Date of registration September 30, 2018." @default.
• W3137718127 created "2021-03-29" @default.
• W3137718127 creator A5009376752 @default.
• W3137718127 creator A5009918050 @default.
• W3137718127 creator A5013384569 @default.
• W3137718127 creator A5016161312 @default.
• W3137718127 creator A5017136846 @default.
• W3137718127 creator A5019680927 @default.
• W3137718127 creator A5019881060 @default.
• W3137718127 creator A5024976681 @default.
• W3137718127 creator A5028034089 @default.
• W3137718127 creator A5031300611 @default.
• W3137718127 creator A5031506026 @default.
• W3137718127 creator A5043416056 @default.
• W3137718127 creator A5043575344 @default.
• W3137718127 creator A5045236213 @default.
• W3137718127 creator A5047837719 @default.
• W3137718127 creator A5055480598 @default.
• W3137718127 creator A5057991836 @default.
• W3137718127 creator A5081011064 @default.
• W3137718127 creator A5087767413 @default.
• W3137718127 creator A5089696059 @default.
• W3137718127 creator A5091114658 @default.
• W3137718127 creator A5091312431 @default.
• W3137718127 date "2021-03-25" @default.
• W3137718127 modified "2023-10-18" @default.
• W3137718127 title "Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial" @default.
• W3137718127 cites W1127081604 @default.
• W3137718127 cites W1534815147 @default.
• W3137718127 cites W2019607817 @default.
• W3137718127 cites W2046736751 @default.
• W3137718127 cites W2098428600 @default.
• W3137718127 cites W2107484016 @default.
• W3137718127 cites W2118863192 @default.
• W3137718127 cites W2128035403 @default.
• W3137718127 cites W2138414111 @default.
• W3137718127 cites W2150982823 @default.
• W3137718127 cites W2289841322 @default.
• W3137718127 cites W2330814896 @default.
• W3137718127 cites W2342481353 @default.
• W3137718127 cites W2342564029 @default.
• W3137718127 cites W2561799613 @default.
• W3137718127 cites W2568974466 @default.
• W3137718127 cites W2585407512 @default.
• W3137718127 cites W2589633700 @default.
• W3137718127 cites W2592144107 @default.
• W3137718127 cites W2608790627 @default.
• W3137718127 cites W2736166064 @default.
• W3137718127 cites W2746991247 @default.
• W3137718127 cites W2753432434 @default.
• W3137718127 cites W2757427979 @default.
• W3137718127 cites W2779503684 @default.
• W3137718127 cites W2783137027 @default.
• W3137718127 cites W2808430809 @default.
• W3137718127 cites W2892319317 @default.
• W3137718127 cites W2896600825 @default.
• W3137718127 cites W2904477283 @default.
• W3137718127 cites W2913383852 @default.
• W3137718127 cites W2933124473 @default.
• W3137718127 cites W2940759533 @default.
• W3137718127 cites W2948155539 @default.
• W3137718127 cites W2963476376 @default.
• W3137718127 cites W2999691828 @default.
• W3137718127 cites W3007634463 @default.
• W3137718127 cites W3016806376 @default.
• W3137718127 cites W3016810481 @default.
• W3137718127 cites W3017352435 @default.
• W3137718127 cites W3043703771 @default.
• W3137718127 cites W3092375167 @default.
• W3137718127 doi "https://doi.org/10.1186/s12885-021-08018-w" @default.
• W3137718127 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7993897" @default.
• W3137718127 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33765967" @default.
• W3137718127 hasPublicationYear "2021" @default.
• W3137718127 type Work @default.
• W3137718127 sameAs 3137718127 @default.
• W3137718127 citedByCount "21" @default.
• W3137718127 countsByYear W31377181272021 @default.
• W3137718127 countsByYear W31377181272022 @default.
• W3137718127 countsByYear W31377181272023 @default.
• W3137718127 crossrefType "journal-article" @default.
• W3137718127 hasAuthorship W3137718127A5009376752 @default.
• W3137718127 hasAuthorship W3137718127A5009918050 @default.
• W3137718127 hasAuthorship W3137718127A5013384569 @default.
• W3137718127 hasAuthorship W3137718127A5016161312 @default.
• W3137718127 hasAuthorship W3137718127A5017136846 @default.
• W3137718127 hasAuthorship W3137718127A5019680927 @default.
• W3137718127 hasAuthorship W3137718127A5019881060 @default.
• W3137718127 hasAuthorship W3137718127A5024976681 @default.
• W3137718127 hasAuthorship W3137718127A5028034089 @default.
• W3137718127 hasAuthorship W3137718127A5031300611 @default.
• W3137718127 hasAuthorship W3137718127A5031506026 @default.
• W3137718127 hasAuthorship W3137718127A5043416056 @default.
• W3137718127 hasAuthorship W3137718127A5043575344 @default.
• W3137718127 hasAuthorship W3137718127A5045236213 @default.
• W3137718127 hasAuthorship W3137718127A5047837719 @default.
• W3137718127 hasAuthorship W3137718127A5055480598 @default.
• W3137718127 hasAuthorship W3137718127A5057991836 @default.
• W3137718127 hasAuthorship W3137718127A5081011064 @default.
• W3137718127 hasAuthorship W3137718127A5087767413 @default.
• W3137718127 hasAuthorship W3137718127A5089696059 @default.

• next